RetinalGenix Technologies Inc. (RTGN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -2 | - | ||||||
| Net profit | $m | -2 | -2 | -4 | -2 | -4 | -2 | -2 | - |
| EPS reported | $ | -0.13 | -0.11 | ||||||
| Operating cashflow per share | $ | -0.03 | -0.03 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.03 | -0.03 | ||||||
| Free cash flow | $m | -1 | -0 | ||||||
| Net debt | $m | 0 | 0 | ||||||
| Book value equity | $m | -2 | -3 | ||||||
| Book value per share | $ | -0.12 | -0.14 | ||||||
| Number of shares | m | 18.56 | 18.81 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -25.80 | -22.49 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -106.39 | -124.28 | ||||||
| EV/EBITDA LTM | x | -24.54 | 172.50 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -4.09% | -3.24% | ||||||
| FCF Yield | % | -0.94% | -0.80% | ||||||
| Quality | |||||||||
| ROE | % | +105.47% | +107.91% | ||||||
| ROIC | % | +1.08% | +22.80% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -10.05 | -8.75 | ||||||
| Net Debt/EBITDA | x | -0.02 | -193.27 | ||||||
| EBIT/Net interest | x | -605.39 | -131.02 | ||||||
| Net debt/market cap | % | +0.09% | +0.07% | ||||||
| Net debt/Equity | x | -0.02 | -0.01 | ||||||
| Gross debt/equity | x | -0.02 | -0.02 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients. Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners. The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
RetinalGenix Technologies Inc. (RTGN)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients. Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners. The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free